Clareo Health | STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
This is a multicentre, randomised, single-blind, placebo-controlled, two-arm parallel group study assessing the effect of anaemia correction and Hb maintenance with darbepoetin alfa in elderly CKD patients for 36 weeks.
Age
70–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stage 3-5 CKD not on dialysis
Patients ≥ 70 years of age
Haemoglobin \< 110g/L at screening
Transferrin saturation ≥ 15% at screening
You may not be if
Clinical history of type 2 diabetes mellitus
Anticipating or scheduled to go on renal replacement therapy in the next year, including renal transplant
Uncontrolled hypertension on two separate measurements during screening
Use of any erythropoietic protein within 12 weeks of screening
